DOCSLIB.ORG

Solubility Challenges: Unlocking a Drug’S Potential JULY 2015 Pharmtech.Com

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Solubility Challenges: Unlocking a Drug’S Potential JULY 2015 Pharmtech.Com JULY 2015 Volume 39 Number 7 Volume 39 Number 7 Cleaning Stability Tablet Count PLUS: Validation of Biologics in Packaging PHARMACEUTICAL TECHNOLOGY Solubility Challenges: Unlocking a Drug’s Potential JULY 2015 2015 JULY PharmTech.com PEER-REVIEWED Using In-Situ Gelling to Optimize Opthalmic Drug Delivery DRUG DELIVERY OPERATIONAL EXCELLENCE API SYNTHESIS & MANUFACTURING Targeting Drugs to the Colon Data Integrity Continuous API Synthesis magentablackcyanyellow ES639585_PT0715_cv1.pgs 07.07.2015 20:54 ADV magentablackcyanyellow ES639144_PT0715_CV2_FP.pgs 07.06.2015 20:46 ADV INTRODUCING Vion IMS QTof When you’re up against complex samples, sometimes resolution and accurate mass aren’t enough to give you all the information you need. Enter Vion IMS QTof with Collision Cross Section (CCS). A new mass spectrometer that brings ion mobility to the benchtop like never before. Now the analytes you didn’t know were there have nowhere to hide. To learn more, visit waters.com/VION PHARMACEUTICAL n HEALTH SCIENCES n FOOD n ENVIRONMENTAL n CHEMICAL MATERIALS magentablackcyanyellow ES639166_PT0715_003_FP.pgs 07.06.2015 20:46 ADV EDITORIAL SALES Editorial Director Rita Peters [email protected] Publisher Mike Tracey [email protected] Senior Editor Agnes Shanley [email protected] Director of Sales Paul Milazzo [email protected] Managing Editor Susan Haigney [email protected] Mid-West Sales Manager Irene Onesto [email protected] Science Editor Adeline Siew, PhD [email protected] East Coast Sales Manager Joel Kern [email protected] Manufacturing Editor Jennifer Markarian [email protected] European Sales Manager Chris Lawson [email protected] Science Editor Randi Hernandez [email protected] European Senior Sales Executive Stephen Cleland [email protected] Community Editor Ashley Roberts [email protected] Executive Assistant Barbara Sefchick [email protected] Art Director Dan Ward; Graphic Designer Courtralingam Madasamy Address Contributing Editors Jill Wechsler [email protected]; Jim Miller info@ 485 Route One South, Building F, Second Floor, Iselin, NJ 08830, USA pharmsource.com; Hallie Forcinio [email protected]; Susan J. Schniepp Tel. 732.596.0276, Fax 732.647.1235 [email protected]; Eric Langer [email protected]; PharmTech.com and Cynthia A. Challener, PhD [email protected] Correspondent Sean Milmo (Europe, [email protected]) Sr. Production Manager Karen Lenzen 485 Route One South, Building F, Second Floor, Iselin, NJ 08830, USA International Licensing Maureen Cannon [email protected], Tel. 732.596.0276, Fax 732.647.1235, PharmTech.com tel. 440.891.2742 or toll-free 800.225.4569 ext 2742, fax. 440.756.5255 Audience Development Manager Rochelle Ballou [email protected] EDITORIAL ADVISORY BOARD Pharmaceutical Technology publishes contributed technical articles that undergo a UBM LIFE SCIENCES rigorous, double-blind peer-review process involving members of our distinguished Joe Loggia, Chief Executive Officer Tom Ehardt, Executive Vice-President, Life Editorial Advisory Board. Manuscripts should be sent directly to the managing editor. Below is a partial list of the Pharmaceutical Technology brand editorial advisory members. The full board, which includes advisory Sciences Georgiann DeCenzo, Executive Vice-President Chris DeMoulin, Executive members from Pharmaceutical Technology Europe, can be found online at PharmTech.com. Vice-President Rebecca Evangelou, Executive Vice-President, Business Systems Julie Molleston, Executive Vice-President, Human Resources Mike Alic, Executive James P. Agalloco R. Gary Hollenbeck, PhD Wendy Saffell-Clemmer Vice-President, Strategy & Business Development Tracy Harris, Sr Vice-President President, Chief Scientific Officer, Director, Research Dave Esola, Vice-President, General Manager Pharm/Science Group Agalloco & Associates UPM Pharmaceuticals BioPharma Solutions Michael Bernstein, Vice-President, Legal Francis Heid, Vice-President, Larry L. Augsburger, PhD Ruey-ching (Richard) Hwang, PhD Gurvinder Singh Rekhi, PhD Media Operations Adele Hartwick, Vice-President, Treasurer & Controller Professor Emeritus Senior Director, Department of Pharmaceutical and University of Maryland Pharmaceutical Sciences, Biomedical Sciences, Pfizer Global R&D The University of Georgia College UBM AMERICAS David H. Bergstrom, PhD of Pharmacy Senior Vice-President, Mansoor A. Khan, PhD Sally Shankland, Chief Executive Officer Brian Field, Chief Operating Officer Pharmaceutical Development & Director, FDA/CDER/DPQR Susan J. Schniepp Margaret Kohler, Chief Financial Officer Corporate Quality Assurance Fellow Russell E. Madsen Antares Pharma, Inc. Regulatory Compliance Associates President, The Williamsburg Phil Borman Group, LLC David R. Schoneker UBM PLC QbD Lead & Data Management & Director of Global Regulatory Affairs, Heidi M. Mansour, PhD Tim Cobbold, Chief Executive Officer Andrew Crow, Group Operations Director Analysis Manager Colorcon Professor, Robert Gray, Chief Financial Officer Dame Helen, Alexander Chairman GlaxoSmithKline College of Pharmacy, Eric B. Sheinin, PhD Rory Budihandojo University of Arizona–Tucson President, Director, Quality and EHS Audit, Sheinin and Associates Jim Miller Boehringer Ingelheim Shanghai President, Aloka Srinivasan Pharmaceuticals Co. (China) PharmSource Information Principal Consultant, Todd L. Cecil Services Bio/Pharmaceutical PAREXEL International Vice-President Outsourcing Report Heinz Sucker, PhD Compendial Science Colin Minchom, PhD Professor Emeritus, United States Pharmacopeia Vice-President, Particle Design Pharmaceutical Institute, University of Bern Metin Çelik, PhD Hovione Scott Sutton, PhD President, Christine Moore, PhD Microbiology Network Pharmaceutical Technologies Deputy Director for Science and ©2015 Advanstar Communications Inc. All rights reserved. No part of this publication may be reproduced or International (PTI) Policy, Office of New Drug Quality transmitted in any form or by any means, electronic or mechanical including by photocopy, recording, or informa- Zak T. Chowhan, PhD Assessment, CDER, FDA Read board members’ tion storage and retrieval without permission in writing from the publisher. Authorization to photocopy items for biographies online at internal/educational or personal use, or the internal/educational or personal use of specific clients is granted by Consultant, Pharmaceutical R. Christian Moreton, PhD Development PharmTech.com/ Advanstar Communications Inc. for libraries and other users registered with the Copyright Clearance Center, 222 Vice-President, Pharmaceutical Rosewood Dr. Danvers, MA 01923, 978-750-8400 fax 978-646-8700 or visit http://www.copyright.com online. Suggy S. Chrai, PhD Sciences, Finnbrit Consulting pharmtech-editorial- advisory-board. For uses beyond those listed above, please direct your written request to Permission Dept. fax 440-756-5255 or President and CEO, Fernando J. Muzzio, PhD email: [email protected]. Chrai Associates, Inc. Director, NSF Engineering UBM Life Sciences provides certain customer contact data (such as customers name, addresses, phone numbers, Roger Dabbah, PhD Research Center on Structured and e-mail addresses) to third parties who wish to promote relevant products, services, and other opportunities that Principal Consultant, Organic Particulate Systems, may be of interest to you. If you do not want UBM Life Sciences to make your contact information available to third Tri-Intersect Solutions Dept. of Chemical and Biochemical parties for marketing purposes, simply call toll-free 866.529.2922 between the hours of 7:30 a.m. and 5 p.m. CST and Engineering, Rutgers University Tim Freeman a customer service representative will assist you in removing your name from UBM Life Sciences’ lists. Outside the US, Managing Director, Moheb M. Nasr, PhD please phone 218.740.6477. FreemanTechnology Vice-President, CMC Regulatory Pharmaceutical Technology does not verify any claims or other information appearing in any of the advertise- Strategy, Global Regulatory Affairs, ments contained in the publication, and cannot take responsibility for any losses or other damages incurred by Sanjay Garg, PhD GlaxoSmithKline readers in reliance of such content. Professor, Pharmaceutical Sciences, Garnet E. Peck, PhD Pharmaceutical Technology welcomes unsolicited articles, manuscripts, photographs, illustrations, and other University of South Australia Professor Emeritus of Industrial materials but cannot be held responsible for their safekeeping or return. Pharmacy, Purdue University Single issues, back issues: Call toll-free 800.598.6008. Outside the US call 218.740.6480. Reprints of all articles in this issue and past issues of this publication are available. Call 877-652-5295 ext. 121 or email bkolb@wrightsmedia. com. Outside US, UK, direct dial: 281-419-5725. Ext. 121. Direct mail lists: Contact Tamara Phillips, Marketing Pharmaceutical Technology’s eNewsletter Team: Services, tel. 440.891.2773, [email protected]. Display, Web, Classified, and Recruitment Advertising: • ePT, Editor Ashley Roberts, [email protected] Contact Tod McCloskey, tel. 440.891.2739, [email protected]. Permissions: Contact Maureen Cannon, • Sourcing and Management, Editor Rita Peters, [email protected] tel. 440.891.2742 or toll-free 800.225.4569 ext 2742, fax. 440.756.5255, [email protected]. • Equipment & Processing Report, Editor Jennifer Markarian, [email protected] To subscribe: Call toll-free 888.527.7008. Outside the
Load more

Recommended publications
  • WHO Drug Information Vol
    WHO Drug Information Vol. 24, No. 4, 2010 World Health Organization WHO Drug Information Contents WHO Prequalification Sitaxentan: worldwide withdrawal 307 Programmes Sibutramine: suspension of sales 307 Sibutramine-containing medicines: WHO Prequalification of Medicines withdrawal 308 Programme: survey of service Testosterone transdermal patch: quality provided to manufacturers 293 withdrawal of extension of WHO initiates pilot prequalification of indication application 308 active pharmaceutical ingredients 297 Aliskiren/valsartan: withdrawal of New on-line database for WHO marketing authorization application 308 prequalified vaccines 298 Mometasone furoate/formoterol fumarate: withdrawal of marketing Safety and Efficacy Issues authorization application 309 EMA and US FDA extend confidentiality H1N1 influenza vaccine: narcolepsy 299 arrangements indefinitely 309 Statins: interstitial lung disease 299 Tocilizumab: risk of fatal anaphylaxis 300 Recent Publications, Pioglitazone: potential bladder cancer 301 Information and Events Angiotensin receptor blockers and US Government to share patents with cancer: safety review 301 Medicines Patent Pool 310 GnRH agonists, diabetes and cardio- Clinical trials and global medicines vascular disease 301 development 310 Gadolinium-based contrast agents: Evaluation of future nanomedicines 311 kidney dysfunction 302 Reporting on opioid inaccessibility 311 Lamotrigine: aseptic meningitis Tinzaparin sodium: renal Impairment in elderly 303 Consultation Documents Tamoxifen: drug interactions involving The
    [Show full text]
  • 2018 Medicines in Development for Skin Diseases
    2018 Medicines in Development for Skin Diseases Acne Drug Name Sponsor Indication Development Phase ADPS topical Taro Pharmaceuticals USA acne vulgaris Phase II completed Hawthorne, NY www.taro.com AOB101 AOBiome acne vulgaris Phase II (topical ammonia oxidizing bacteria) Cambridge, MA www.aobiome.com ASC-J9 AndroScience acne vulgaris Phase II (androgen receptor degradation Solana Beach, CA www.androscience.com enhancer) BLI1100 Braintree Laboratories acne vulgaris Phase II completed Braintree, MA www.braintreelabs.com BPX-01 BioPharmX acne vulgaris Phase II (minocycline topical) Menlo Park, CA www.biopharmx.com BTX1503 Botanix Pharmaceuticals moderate to severe acne vulgaris Phase II (cannabidiol) Plymouth Meeting, PA www.botanixpharma.com CJM112 Novartis Pharmaceuticals acne vulgaris Phase II (IL-17A protein inhibitor) East Hanover, NJ www.novartis.com clascoterone Cassiopea acne vulgaris Phase III (androgen receptor antagonist) Lainate, Italy www.cassiopea.com Medicines in Development: Skin Diseases ǀ 2018 Update 1 Acne Drug Name Sponsor Indication Development Phase CLS001 Cutanea acne vulgaris Phase II (omiganan) Wayne, PA www.cutanea.com DFD-03 Promius Pharma acne vulgaris Phase III (tazarotene topical) Princeton, NJ www.promiuspharma.com DMT310 Dermata Therapeutics moderate to severe acne vulgaris Phase II (freshwater sponge-derived) San Diego, CA www.dermatarx.com finasteride Elorac severe nodulocystic acne Phase II (cholestenone 5-alpha Vernon Hills, IL www.eloracpharma.com reductase inhibitor) FMX101 Foamix moderate to severe
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Crth2: Can Residence Time Help ?
    CRTh2: Can Residence Time Help ? RSC-SCI Cambridge Medicinal Chemistry Symposium Churchill College, Cambridge 8-11 September 2013 Rick Roberts Almirall Introduction Paul Ehrlich, The Lancet (1913), 182, 445 “A substance will not work unless it is bound” 100 years on: “What a substance does may depend on how long it is bound” 2 In a nutshell …. Introduction “Applications of Binding Kinetics to Drug Discovery” D. Swinney, Pharm. Med. (2008), 22, 23-34 3 Energetic concept of Residence Time kon Standard model [R] + [L] [RL] k unbound off bound Energy ‡ Binding process (kon) is (R·L) determined by the energy barrier Ea E Ligand concentration a Unbinding process (koff) is determines the number of Ed determined by the energy attempts to get over this barrier Ed barrier [R] + [L] G = Ed -Ea [RL] Reaction coordinate Potency (Ki) is determined by the difference in these energies koff Ki = kon 4 K , k , k i on off -1 -1 kon M s Potency (nM) vs kon vs koff Very fast association 108 10 1 0.1 0.01 0.001 107 100 10 1 0.1 0.01 0.001 fast association 106 1000 100 10 1 0.1 0.01 0.001 105 10 M 1000 100 10 1 0.1 0.01 0.001 slow association 104 10 M 1000 100 10 1 0.1 0.01 Very slow association 103 10 M 1000 100 10 1 0.1 “inactive” 102 10 M 1000 100 10 1 10 10-1 10-2 10-3 10-4 10-5 10-6 10-7 s-1 koff Energy A simple binding measurement gives no clue to how fast the association and dissociation are (R·L)‡ Very slow associating compounds that are very slow dissociating (R·L)‡ slow associating compounds that are slow dissociating Are all fast associating compounds
    [Show full text]
  • Prostanoid Receptors (Version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database
    IUPHAR/BPS Guide to Pharmacology CITE https://doi.org/10.2218/gtopdb/F58/2019.5 Prostanoid receptors (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database Richard M. Breyer1, Lucie Clapp2, Robert A. Coleman3, Mark Giembycz4, Akos Heinemann5, Rebecca Hills6, Robert L. Jones7, Shuh Narumiya8, Xavier Norel9, Roy Pettipher10, Yukihiko Sugimoto11, Mohib Uddin12, David F. Woodward13 and Chengcan Yao6 1. Vanderbilt University, USA 2. University College London, UK 3. Pharmagene Laboratories, UK 4. University of Calgary, Canada 5. Otto Loewi Research Center (for Vascular Biology, Immunology and Inflammation), Austria 6. University of Edinburgh, UK 7. University of Strathclyde, UK 8. Kyoto University Faculty of Medicine, Japan 9. Laboratory for Vascular Translational Science, France 10. Atopix Therapeutics Ltd, UK 11. Kumamoto University, Japan 12. AstraZeneca, Sweden 13. Allergan plc, USA Abstract Prostanoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Prostanoid Receptors [659]) are activated by the endogenous ligands prostaglandins PGD2, PGE1, PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Measurement of the potency of PGI2 and thromboxane A2 is hampered by their instability in physiological salt solution; they are often replaced by cicaprost and U46619, respectively, in receptor characterization studies. Contents This is a citation summary for Prostanoid receptors in the Guide to Pharmacology database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links. GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them.
    [Show full text]
  • Is It Too Late? PAGE 58
    MOST TRUSTED & MOST READ Is It Too Late? PAGE 58 On Board the HowtoSpot Friendship Online Bus Love Scams PAGE 26 PAGE 30 6 Silent Diabetes Symptoms You’re Missing PAGE 16 He’sGotaGun! The Hijack on Baldness Flight 918 Business PAGE 50 PAGE 116 Kindness of Strangers ................................. 12 News Worth Sharing ..................................130 1 FREE % PLUS 40OFF ISSUE + A SPECIAL FREE GIFT Every issue of Reader’s Digest offers only the best original writing on issues that MOST TRUSTED& matter to you. MOST READ Real-life dramas and uplifting stories, amazing NG THE health discoveries and human adventure. PANDA Long reads mixed Is It TooPAGE Late? 58 with short stories. HowtoSpot PLUS exclusive On Board the Online book excerpts. Friendship Bus Love Scams PAGE 30 PAGE 26 + Only $48 for 12 issues. 6 That’s just $4.00 per issue, Silent Diabetes instead of $6.50 at retail Symptoms You’re Missing PAGE 16 + EXTRA ISSUE FREE to He’sGotaGun! The enjoy with our compliments Baldness Hijack on DELIVERY included Business + Flight 918 PAGE 116 every month PAGE 50 12 ................................. PLUS a special free gift Kindness of Strangers + ..................................130 News Worth Sharing TO ORDER: ASIA: rdasia.com/get-the-magazine AUSTRALIA: readersdigest.com.au/subscribe NEW ZEALAND: readersdigest.co.nz/subscribe Contents FEBRUARY 2018 Heart 26 FRIENDSHIP BUS Kiwi filmmaker Julie Zhu takes a bus trip with grandparents who bond over bargains. INDIA HENDRIKSE FROM WWW.NOTED.CO.NZ Crime Watch 30 LONELY HEART SCAMS How online criminal networks defraud lonely people with false promises of romance and love. HELEN SIGNY Nature 40 THE TREES ARE TALKING Nature is networking in the forest via the ‘wood wide web’.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Inflammation/Immunology
    Inflammation/Immunology The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency. www.MedChemExpress.com 1 Inflammation/Immunology Inhibitors & Modulators (+)-Borneol (+)-DHMEQ ((1R,2R,6R)-Dehydroxymethylepoxyquinomicin; (d-Borneol) Cat. No.: HY-N1368A (1R,2R,6R)-DHMEQ) Cat. No.: HY-14645A Bioactivity: (+)-Borneol (d-Borneol) is a natural bicyclic monoterpene used Bioactivity: (+)-DHMEQ is an activator of antioxidant transcription factor for analgesia and anesthesia in traditional Chinese medicine; Nrf2. (+)-DHMEQ is the enantiomer of (-)-DHMEQ. (-)-DHMEQ enhances GABA receptor activity with an EC50 of 248 μM. inhibits NF-kB than its enantiomer (+)-DHMEQ. Purity: 98.0% Purity: 98.02% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 100 mg 2 mg, 5 mg, 10 mg, 25 mg (-)-Epicatechin (-)-Ketoconazole ((-)-Epicatechol; Epicatechin; epi-Catechin) Cat. No.: HY-N0001 Cat. No.: HY-B0105B Bioactivity: (-)-Epicatechin inhibits cyclooxygenase-1 ( COX-1) with an Bioactivity: (-)-Ketoconazole is one of the enantiomer of Ketoconazole. Ketoconazole is a racemic mixture of two enantiomers, IC50 of 3.2 μM. (-)-Epicatechin inhibits the IL-1β-induced expression of iNOS by blocking the nuclear localization of the levoketoconazole ((2S,4R)-(−)-ketoconazole) and p65 subunit of NF-κB.
    [Show full text]
  • Regrow Hair Protocol Ingredients
    Regrow Hair Protocol Ingredients Astronomic and buxom Matty often skewers some neoclassicism revilingly or spoken high-mindedly. Blue-collar Maurice hazed schematically or powdery movelessly when Reinhard is electroacoustic. When Melvin fertilising his Ngunis fins not dynastically enough, is Ware interbank? But I would say, why stop if you want to keep your hair? There must be something hidden. Both men with regrow hair protocol ingredients such as soon, ingredients together to notice and i just as a cup of preying on. This website uses cookies to improve your experience while you navigate through the website. Aga and women see what does jojoba oil for hair protocol program depends on a guy had a tv, ingredients regrow hair growth. This means people can still enjoy eating what they like. In contrast, minoxidil is almost completely absorbed from the gastrointestinal tract following oral administration of minoxidil tablets. An effective cocktail contains at least two to three principal agents. Or is this an increase that has taken place during the recent years? Already have an account? Radiation induces a huge trigger baldness in my guess that warrant doing so that comes from ingredients regrow hair protocol of cream and looks. Curious to see how hair restoration could enhance your natural beauty? Apply it on your scalp and gently massage. Revitalizes hair follicles by regenerating hair cells. Hay IC, et al. Rosemary oil, but if you find it works then it would seem to be fine for you. These ingredients effectively block the receptor site which is responsible for hindering hair growth. It sounds like they have been working hard behind the scenes to make advancements in their products.
    [Show full text]
  • The Biology of Prostaglandins and Their Role As a Target for Allergic Airway Disease Therapy
    International Journal of Molecular Sciences Review The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy Kijeong Lee, Sang Hag Lee and Tae Hoon Kim * Department of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, Seoul 02841, Korea; [email protected] (K.L.); [email protected] (S.H.L.) * Correspondence: [email protected]; Tel.: +82-02-920-5486 Received: 23 January 2020; Accepted: 5 March 2020; Published: 8 March 2020 Abstract: Prostaglandins (PGs) are a family of lipid compounds that are derived from arachidonic acid via the cyclooxygenase pathway, and consist of PGD2, PGI2, PGE2, PGF2, and thromboxane B2. PGs signal through G-protein coupled receptors, and individual PGs affect allergic inflammation through different mechanisms according to the receptors with which they are associated. In this review article, we have focused on the metabolism of the cyclooxygenase pathway, and the distinct biological effect of each PG type on various cell types involved in allergic airway diseases, including asthma, allergic rhinitis, nasal polyposis, and aspirin-exacerbated respiratory disease. Keywords: prostaglandins; allergy; asthma; allergic rhinitis; AERD; PGD2; PGE2 1. Introduction Prostaglandins (PGs) are lipid mediators, generated from arachidonic acid (AA) metabolism via cyclooxygenases (COX). They were discovered in the 1930s as regulators of blood pressure and smooth muscle contraction [1]. The distribution of synthases and receptors for each PG is different in various cell types, and PGs are activated via either paracrine or autocrine signaling on the surface of each cell type [2]. PGs bridge the interactions between various immune-modulating cells, and are considered key players in regulating pro-inflammatory and anti-inflammatory responses [3].
    [Show full text]
  • And 1,4‒Additions Enabled by Asymmetric Organocatalysis
    STEREOSELECTIVE 1,2‒ AND 1,4‒ADDITIONS ENABLED BY ASYMMETRIC ORGANOCATALYSIS Jennifer Lynn Fulton A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Chemistry in the College of Arts and Sciences. Chapel Hill 2020 Approved by: Jeffrey Johnson Marcey Waters Frank Leibfarth Jeffrey Aubé Simon Meek © 2020 Jennifer Lynn Fulton ALL RIGHTS RESERVED ii ABSTRACT Jennifer Lynn Fulton: Stereoselective 1,2‒ and 1,4‒Additions Enabled by Asymmetric Organocatalysis (Under the direction of Jeffrey S. Johnson) I. Enantio- and Diastereoselective Organocatalytic Conjugate Additions of Nitroalkanes to Enone Diesters Enantio- and diastereoselective conjugate addition reactions between nitroethane or nitropropane and enone diesters are described. A bifunctional triaryliminophosphorane catalyzed the addition reaction with consistently excellent stereoselectivities and yields across a wide range of substrates. Using the geminal diester functional handle present in the adducts, local desymmetrization via diastereotopic group discrimination was demonstrated and a polyfunctionalized lactam with three contiguous stereocenters was synthesized. II. Asymmetric Organocatalytic Sulfa-Michael Addition to Enone Diesters iii An asymmetric sulfa-Michael addition of alkyl thiols to enone diesters is reported. The reaction is catalyzed by a bifunctional triaryliminophosphorane-thiourea organocatalyst and provides a range of α-sulfaketones in high yields and enantioselectivities. Leveraging the gem- diester functional handle via a subsequent diastereotopic group discrimination generates functionalized lactones with three contiguous stereocenters. III. Efforts Towards the Reduction of α-Imino Esters via Dynamic Kinetic Resolution Efforts toward the enantioconvergent trichlorosilane-mediated reduction of β- substituted α-imino esters are described.
    [Show full text]